Y. Bignon

J. Simard, D. Yannoukakos, J. Peyrat, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

BRCA 1 Wild-Type Allele Modifies Risk of Ovarian Cancer in Carriers of BRCA 1 GermLine Mutations 1

J. Simard, D. Yannoukakos, J. Peyrat, 2003 .

Phytoestrogen-rich diets modulate expression of Brca1 and Brca2 tumor suppressor genes in mammary glands of female Wistar rats.

Y. Bignon, D. BERNARD-GALLON, M. Horcajada, 2003, Cancer research.

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

M. Urioste, P. Chanson, M. Blok, 2012, Clinical Cancer Research.

Partial lipodystrophy with severe insulin resistance and adult progeria Werner syndrome

B. Donadille, C. Vigouroux, Y. Bignon, 2013, Orphanet Journal of Rare Diseases.

Genome-wide DNA methylation modified by soy phytoestrogens: role for epigenetic therapeutics in prostate cancer?

Y. Bignon, A. Lebert, D. BERNARD-GALLON, 2015, Omics : a journal of integrative biology.

Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines

Y. Bignon, P. Fustier, D. BERNARD-GALLON, 2002, British Journal of Nutrition.

Consanguinity Protecting Effect Against Breast Cancer among Tunisian Women: Analysis of BRCA1 Haplotypes.

Y. Bignon, A. Elgaaied, C. Sibille, 2015, Asian Pacific journal of cancer prevention : APJCP.

Effects of the Phytoestrogens Genistein and Daidzein on BRCA2 Tumor Suppressor Gene Expression in Breast Cell Lines

Y. Bignon, D. BERNARD-GALLON, C. Vissac-Sabatier, 2003, Nutrition and cancer.

Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status.

Y. Bignon, D. BERNARD-GALLON, C. Vissac, 2002, Clinica chimica acta; international journal of clinical chemistry.

Breast Cancer and Lycopene

Y. Bignon, N. Chalabi, D. BERNARD-GALLON, 2019, Lycopene.

Long-term improved quality of life by a 2-week group physical and educational intervention shortly after breast cancer chemotherapy completion. Results of the “Programme of Accompanying women after breast Cancer treatment completion in Thermal resorts” (PACTHE)

Y. Bignon, F. Kwiatkowski, A. Léger-Enreille, 2014 .

BRCA1/BRCA2 Mutations Shaped by Ancient Consanguinity Practice in Southern Mediterranean Populations

Y. Bignon, S. Boussetta, Y. Bidet, 2018, Asian Pacific journal of cancer prevention : APJCP.

Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia

Y. Bignon, L. Chouchane, A. Elgaaied, 2007, Journal of Human Genetics.

Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.

W. Foulkes, D. Lambrechts, O. Cussenot, 2021, European journal of cancer.

Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.

A. Børresen-Dale, C. Larsson, Å. Borg, 1998, Cancer research.

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing

M. Bihoreau, N. Servant, D. Stoppa-Lyonnet, 2018, International journal of cancer.

Central adiposity as a major risk factor of ovarian cancer.

Y. Bignon, F. Kwiatkowski, N. Chalabi, 2009, Anticancer research.

Nutrigenomics and antioxidants.

Y. Bignon, M. Vasson, N. Chalabi, 2008, Personalized medicine.

Cancer genetic consultation and anxiety in healthy consultees

Y. Bignon, H. Sobol, C. Julian‐Reynier, 1999 .

Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines

Y. Bignon, D. BERNARD-GALLON, P. Dechelotte, 2012, British Journal of Nutrition.

Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy.

Y. Bignon, D. BERNARD-GALLON, Samir Satih, 2009, In vivo.

Biological Effects of Soy Isoflavones

Y. Bignon, D. BERNARD-GALLON, L. Guy, 2012 .

DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human

Y. Bignon, Rémy Bosviel, N. Rabiau, 2011 .

The association between Histone 3 Lysine 27 Trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters

Y. Bignon, A. Lebert, D. BERNARD-GALLON, 2014, BMC Cancer.

Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon

E. Chouery, A. Mégarbané, Y. Bignon, 2012, Hereditary cancer in clinical practice.

Exploring the link between MORF4L1 and risk of breast cancer

S. Seal, N. Rahman, F. Couch, 2011, Breast Cancer Research.

Soya phytonutrients act on a panel of genes implicated with BRCA1and BRCA2 oncosuppressors in human breast cell lines

Y. Bignon, L. Le Corre, N. Chalabi, 2006, British Journal of Nutrition.

Four Years Analysis of Cancer Genetic Clinics Activity in France from 1994 to 1997: A Survey on 801 Patients

D. Stoppa-Lyonnet, Y. Bignon, H. Sobol, 2002, Disease markers.

Expression analyses of nuclear receptor genes in breast cancer cell lines exposed to soy phytoestrogens after BRCA2 knockdown by TaqMan Low-Density Array (TLDA)

Y. Bignon, D. BERNARD-GALLON, Samir Satih, 2009, Journal of molecular signaling.

Effects of GSK-J4 on JMJD3 Histone Demethylase in Mouse Prostate Cancer Xenografts

Y. Bignon, D. BERNARD-GALLON, F. Penault-Llorca, 2022, Cancer Genomics & Proteomics.

High incidence of cancer in a family segregating a mutation of the ATM gene: Possible role of ATM heterozygosity in cancer

M. Vuillaume, J. Hall, Y. Bignon, 1999, Human mutation.

Seventh International Workshop on Ataxia-Telangiectasia1

Y. Bignon, J. Bay, N. Uhrhammer, 1998 .

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

W. Chung, J. Benítez, R. Eeles, 2020, Breast Cancer Research.

Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen

Y. Bignon, F. Caldefie‐Chézet, M. Vasson, 2015, PloS one.

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

J. Lemonnier, P. Pujol, J. Fricker, 2011, Familial Cancer.

Germline mutations of the E‐cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer

Y. Bignon, Xiaoming Xie, N. Uhrhammer, 2011, Cancer.

Prophylactic oophorectomy

F. Penault-Llorca, C. Cohen, Y. Bignon, 2003, Cancer.

Linkage analysis of 19 French breast cancer families, with five chromosome 17q markers.

B. Dutrillaux, S. Mazoyer, Y. Bignon, 1993, American journal of human genetics.

DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort.

Y. Bignon, F. Kwiatkowski, N. Chalabi, 2008, Anticancer research.

Genistein and daidzein: different molecular effects on prostate cancer.

Y. Bignon, D. BERNARD-GALLON, L. Guy, 2013, Anticancer research.

Detection of epstein‐barr viral genomes in lymph nodes of Hodgkin's disease patients

B. Dastugue, Y. Bignon, H. Curé, 1990, Molecular carcinogenesis.

Survey of Cutaneous T Cell Lymphomas for Human T-Lymphotropic Virus Infection

Y. Bignon, P. Souteyrand, C. Desgranges, 1994 .

Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells.

Y. Bignon, D. BERNARD-GALLON, P. Dechelotte, 2010, In vivo.

Exploring the link between MORF4L1 and risk of breast cancer

S. Seal, N. Rahman, F. Couch, 2011 .

Quantification by affinity perfusion chromatography of phosphorylated BRCAl and BRCA2 proteins from tumor cells after lycopene treatment.

Y. Bignon, L. Le Corre, N. Chalabi, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls.

Y. Bignon, F. Kwiatkowski, D. BERNARD-GALLON, 2012, Cancer epidemiology.

Determination of BRCA2 oncosuppressor protein expression in human mammary cells by affinity perfusion high-performance chromatography.

Y. Bignon, D. BERNARD-GALLON, J. Maurizis, 2001, Journal of biochemical and biophysical methods.

Linkage analysis of 56 multiplex families excludes the Cowden disease genePTEN as a major contributor to familial breast cancer

D. Easton, S. Seal, M. Stratton, 1999, Journal of medical genetics.

[Ovarian carcinogenesis: recent and past hypotheses].

F. Penault-Llorca, I. Ray-Coquard, Y. Bignon, 2011, Gynecologie, obstetrique & fertilite.

Breast cancer cell response to genistein is conditioned by BRCA1 mutations.

Y. Bignon, M. Ferrara, C. Aubel, 2009, Biochemical and biophysical research communications.

Status of antioxidant enzyme: glutathione peroxidase and total polyphenol level in plasma of Tunisian patients suffering from colorectal and gastric cancer: interaction with clinical outcome

Y. Bignon, N. Uhrhammer, S. Ellouz, 2013, Medical Oncology.

Gene signature of rat mammary glands: Influence of lifelong soy isoflavones consumption.

Y. Bignon, N. Chalabi, D. BERNARD-GALLON, 2009, Molecular medicine reports.

Influence of genistein and daidzein on Brca1 protein levels in human breast cell lines.

Y. Bignon, D. BERNARD-GALLON, J. Maurizis, 1998, Journal of the National Cancer Institute.

Soy Phytoestrogens and Breast Cancer Chemoprevention: Molecular Mechanisms

Y. Bignon, D. BERNARD-GALLON, Samir Satih, 2008 .

DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines.

Y. Bignon, D. BERNARD-GALLON, Rémy Bosviel, 2011, Epigenomics.

The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression.

Y. Bignon, L. Le Corre, D. BERNARD-GALLON, 2004, European journal of cancer.

Presence of BRCA1 and BRCA2 proteins in human milk fat globules after delivery.

Y. Bignon, P. Fustier, L. Le Corre, 2002, Biochimica et biophysica acta.

BRCA2 mutations in hereditary breast and ovarian cancer in France.

R. Lidereau, G. Lenoir, S. Mazoyer, 1997, American journal of human genetics.

BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.

F. Jamali, M. Seoud, Y. Bignon, 2015, The oncologist.

Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition

Y. Bignon, N. Uhrhammer, Y. Bidet, 2020, Genes, chromosomes & cancer.

Permanence of the information given during oncogenetic counseling to persons at familial risk of breast/ovarian and/or colon cancer

Y. Bignon, F. Kwiatkowski, Pascal Dessenne, 2011, European Journal of Human Genetics.

Lineage promiscuity in leukemia studies of T-cell receptor and immunoglobulin genes.

Y. Bignon, H. Curé, F. Demeocq, 1993, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Clonotypic Heterogeneity in Cutaneous T-Cell Lymphomas1

B. Dastugue, Y. Bignon, P. Souteyrand, 2006 .

Genotypic analyses of richter's syndrome

Y. Bignon, P. Chollet, F. Courjal, 1991, Cancer.

Werner syndrome and mutations of the WRN and LMNA genes in France

Y. Bignon, N. Uhrhammer, S. Aractingi, 2006, Human mutation.

Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines

Y. Bignon, P. Fustier, L. Le Corre, 2003, British Journal of Cancer.

Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines.

Y. Bignon, D. BERNARD-GALLON, C. Hızel, 1999, Biochemical and biophysical research communications.

New mechanism of BRCA-1 mutation by deletion/insertion at the same nucleotide position in three unrelated French breast/ovarian cancer families

Y. Bignon, D. BERNARD-GALLON, A. Hardouin, 1998, Human Genetics.

Effects of Monounsaturated and Polyunsaturated Fatty Acids (v-3 and v-6) on Brca1 Protein Expression in Breast Cell Lines

Y. Bignon, D. BERNARD-GALLON, P. Bougnoux, 1998 .

New nonsense mutation in the breast cancer‐1 gene in a French site‐specific breast cancer family

Y. Bignon, N. Presneau, C. Vaurs, 1997 .

Association between hereditary predisposition to common cancers and congenital multimalformations

Y. Bignon, F. Kwiatkowski, N. Uhrhammer, 2019, Congenital anomalies.

Health management of patients with COVID-19: is there a room for hydrotherapeutic approaches?

Y. Bignon, D. Thivel, M. Duclos, 2022, International Journal of Biometeorology.

Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.

Y. Bignon, S. Lafarge, V. Sylvain, 2002, International journal of oncology.

Genetic Polymorphisms in CYP 1 A 1 , CYP 1 B 1 , COMT , GSTP 1 and NAT 2 Genes and Association with Bladder Cancer Risk in a French Cohort

Y. Bignon, D. BERNARD-GALLON, A. Chamoux, 2009 .

MUTYH-associated polyposis: review and update of the French recommendations established in 2012 under the auspices of the National Cancer Institute (INCa).

J. Saurin, Y. Bignon, B. Buecher, 2020, European journal of medical genetics.

Soy Phytoestrogens on DNA Methylation in Prostate Cancer

Y. Bignon, L. Guy, M. Ngollo, 2017 .

[Don't forget fallopian tubes! A morphologic and immunohistochemical study about Fallopian tubes with genetic risk (BRCA mutation)].

F. Penault-Llorca, Y. Bignon, A. Cayre, 2012, Gynecologie, obstetrique & fertilite.

Subcellular localization of BRCA1 protein in sporadic breast carcinoma with or without allelic loss of BRCA1 gene.

F. Penault-Llorca, M. D. De Latour, Y. Bignon, 1999, International journal of oncology.

A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers

F. Révillion, Chloé-Agathe Azencott, N. Sevenet, 2020, BMC Medical Research Methodology.

Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study

M. Beckmann, A. Børresen-Dale, D. Birnbaum, 1999, Genes, chromosomes & cancer.

Clonotypic heterogeneity in cutaneous T-cell lymphomas.

B. Dastugue, Y. Bignon, P. Souteyrand, 1990, Cancer research.

Cloning and characterization of a retroviral plasmid, pCC1, for combination suicide gene therapy.

Y. Bignon, J. Gäken, M. Kuiper, 2000, BioTechniques.

A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors

Y. Bignon, Amélie Cavard, M. Privat, 2020, International journal of medical sciences.

Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines

Y. Bignon, Justine Rudewicz, M. Privat, 2018, International journal of medical sciences.

Study of T-cell antigen receptor gene rearrangement: a useful tool for early diagnosis of mycosis fungoides.

B. Dastugue, Y. Bignon, P. Souteyrand, 1989, Acta dermato-venereologica.

Loss of heterozygosity at 7q31 in breast cancer: results from an International Collaborative Study Group. The Breast Cancer Somatic Genetics Consortium.

Å. Borg, J. Eyfjörd, P. Devilee, 1997, Genes, chromosomes & cancer.

Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome‐9 deletion

Y. Bignon, P. Catilina, J. Boiteux, 1998, International journal of cancer.

Spectrum of PTCH1 mutations in French patients with Gorlin syndrome.

V. Drouin‐Garraud, D. Lacombe, Y. Bignon, 2003, The Journal of investigative dermatology.

Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

Julian Peto, Ute Hamann, Peter Devilee, 2005, Clinical Cancer Research.

Effect of epidermal growth factor in HLA class I and class II transcription and protein expression in human breast adenocarcinoma cell lines.

Y. Bignon, P. Chollet, F. Courjal, 1992, British Journal of Cancer.

Association between H-ras minisatellite and colorectal cancer risk.

Y. Bignon, F. Kwiatkowski, A. Daver, 1998, Anticancer research.

Evaluation of the 5' spliced form of human cathepsin B mRNA in colorectal mucosa and tumors.

Y. Bignon, D. Pezet, D. BERNARD-GALLON, 1998, Oncology reports.

Immunohistochemical Expression of RARα, RARβ, and Cx43 in Breast Tumor Cell Lines After Treatment With Lycopene and Correlation With RT-QPCR

Y. Bignon, D. BERNARD-GALLON, P. Dechelotte, 2007 .

Immunohistochemical expression of RARalpha, RARbeta, and Cx43 in breast tumor cell lines after treatment with lycopene and correlation with RT-QPCR.

Y. Bignon, N. Chalabi, D. BERNARD-GALLON, 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Early Onset Multiple Primary Tumors in Atypical Presentation of Cowden Syndrome Identified by Whole-Exome-Sequencing

Y. Bignon, N. Uhrhammer, Y. Bidet, 2018, Front. Genet..

Molecular and Epigenetic Biomarkers in Luminal Androgen Receptor: A Triple Negative Breast Cancer Subtype.

Y. Bignon, A. Lebert, D. BERNARD-GALLON, 2016, Omics : a journal of integrative biology.

Title Interplay between BRCA 1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer

Loris, Fiona, Meindl, 2012 .

[Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme].

F. Penault-Llorca, Y. Bignon, C. Pomel, 2011, Annales de pathologie.

Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer.

F. Penault-Llorca, Y. Bignon, F. Mishellany, 2009, European journal of cancer.

Gene Expression in Human Acute Cutaneous and Hepatic Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation.

Y. Bignon, L. Le Corre, N. Chalabi, 2006, Cancer genomics & proteomics.

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

M. Stratton, M. J. van de Vijver, J. Chang-Claude, 1998, Journal of the National Cancer Institute.

B7.1 and Cytokines

F. Farzaneh, Y. Bignon, M. Kuiper, 2002 .

Histoprognostic grade in tumours from families with hereditary predisposition to breast cancer

Y. Bignon, Y. Fonck, M. Chassagne, 1995, The Lancet.

Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.

J. Simard, D. Yannoukakos, J. Peyrat, 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Common BRCA 2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA 1 Mutation Carriers

J. Simard, D. Yannoukakos, J. Peyrat, 2005 .

Inflammatory Breast Carcinoma: The Experience of the Centre Jean Perrin

Y. Bignon, F. Kwiatkowski, A. Janin, 1991 .

Systematic Review of COVID-19-Related Physical Activity-Based Rehabilitations: Benefits to Be Confirmed by More Robust Methodological Approaches

Y. Bignon, D. Thivel, M. Duclos, 2022, International journal of environmental research and public health.

ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide.

Y. Bignon, J. Bay, N. Uhrhammer, 1999, European journal of cancer.

Angioimmunoblastic lymphadenopathy with dysproteinaemia (AILD) and sicca syndrome.

Y. Bignon, J. Dubost, B. Sauvezie, 1986, Annals of the rheumatic diseases.

Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.

Y. Bignon, F. Kwiatkowski, Rémy Bosviel, 2011, Clinica chimica acta; international journal of clinical chemistry.

Lack of germ-line mutations in the p53 gene exons 4 to 8 in patients with late-onset second malignant neoplasms.

Y. Bignon, P. Lalle, C. Moyret, 1994, Cancer genetics and cytogenetics.

Detection of Epstein‐Barr virus sequences in primary brain lymphoma without immunodeficiency

A. Jouvet, B. Dastugue, Y. Bignon, 1991, Neurology.

Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: Implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy

F. Penault-Llorca, Y. Bignon, M. Kuiper, 2000, Cancer Gene Therapy.

BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18–30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial

J. Daurès, Y. Bignon, F. Kwiatkowski, 2016, Trials.

Ethical implications of communicating molecular test results to families with hereditary predisposition to cancer

E. Carasevici, Y. Bignon, N. Uhrhammer, 2013 .

MOLECULAR INSIGHTS ON BASAL-LIKE BREAST CANCER ADVANCES ON BASAL LIKE BREAST CANCER

Y. Bignon, M. Alaoui-Jamali, M. Privat, 2012 .

Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor but significative biological differences.

F. de Longueville, V. Bertholet, J. Remacle, 2008, Cancer genomics & proteomics.

Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sézary syndrome.

Y. Bignon, P. Souteyrand, M. D’Incan, 1992, Archives of dermatology.

[Eosinophilic pustular folliculitis disclosing high-grade rapidly fatal T lymphoma].

Y. Bignon, P. Souteyrand, Y. Fonck, 1988, Annales de dermatologie et de venereologie.

Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines.

Y. Bignon, Myriam Kossaï, M. Braud, 2010, Cancer epidemiology.

Interaction between GSTM1‐null and CYP2D6‐deficient alleles in the pathogenesis of Parkinson's disease

Y. Bignon, É. Albuisson, G. Lucotte, 2004, European journal of neurology.

Screening for microdeletions on the long arm of chromosome Y in 53 infertile men.

I. Seifer, Y. Bignon, S. Amat, 1999, International journal of andrology.

BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection.

Y. Bignon, F. Kwiatkowski, P. Dechelotte, 2011, Oncology reports.

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer

F. Penault-Llorca, Y. Bignon, A. Cayre, 2011, PloS one.

Detection of heterozygous carriers of the ataxia-telangiectasia (ATM) gene by G2 phase chromosomal radiosensitivity of peripheral blood lymphocytes

Y. Bignon, F. Kwiatkowski, J. Bay, 1997, Human Genetics.

Evidence of 3β-hydroxysteroid dehydrogenase activity in several murine embryonal carcinoma cell lines

J. C. Vennat, Y. Bignon, P. Chollet, 1988 .

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.

M. Stratton, M. J. van de Vijver, J. Chang-Claude, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

Michael Jones, Peter Kraft, Arnaud Droit, 2017, Nature Genetics.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

J. S. Hoffman, W. Chung, V. Pankratz, 2012, Human mutation.

Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers

J. Klijn, D. Easton, B. Weber, 2004, Clinical Cancer Research.

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

J. Bergh, M. Olivier, P. Hainaut, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Functions of the Demethylase JMJD3 in Cancer

Y. Bignon, F. Penault-Llorca, L. Guy, 2021, International journal of molecular sciences.

Epi-drugs as triple-negative breast cancer treatment.

Y. Bignon, F. Penault-Llorca, Anna Sanchez, 2020, Epigenomics.

TIP60: an actor in acetylation of H3K4 and tumor development in breast cancer.

Y. Bignon, F. Mishellany, S. Besse, 2018, Epigenomics.

The “extreme phenotype approach” applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles

J. Rivière, R. Boidot, L. Faivre, 2023, Oncotarget.

Resveratrol and breast cancer chemoprevention: molecular mechanisms.

Y. Bignon, L. Le Corre, L. Delort, 2005, Molecular nutrition & food research.

Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.

F. Révillion, R. Lidereau, N. Sevenet, 2021, American journal of human genetics.

CHEK2 contribution to hereditary breast cancer in non-BRCA families

Y. Bignon, N. Uhrhammer, A. Desrichard, 2011, Breast Cancer Research.

High allele loss rates at I7q I2‐q2I in breast and ovarian tumors from BRCAI‐linked families

J. Chang-Claude, B. Ponder, C. Larsson, 1995 .

Low frequency of microsatellite instability inBRCA1 mutated breast tumours

F. Penault-Llorca, Y. Bignon, C. Vaurs-Barrière, 2000, Journal of medical genetics.

Detection of allelic losses on 17q12-q21 chromosomal region in benign lesions and malignant tumors occurring in a familial context.

M. D. De Latour, Y. Bignon, P. Lalle, 1994, Oncogene.

BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk

Y. Bignon, F. Kwiatkowski, N. Uhrhammer, 2015, PloS one.

Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population

E. Carasevici, Y. Bignon, N. Uhrhammer, 2010, Familial Cancer.

Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.

M. D. De Latour, Y. Bignon, F. Kwiatkowski, 1998, International journal of oncology.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment

Y. Bignon, A. El-Gaaied, N. Uhrhammer, 2014, Medical Oncology.

Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines.

Y. Bignon, Y J Bignon, D A Favy, 2000, Biochemical and biophysical research communications.

Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression

Y. Bignon, F. Penault-Llorca, J. Kémény, 2017, BMC Cancer.

A bivalent role of TIP60 histone acetyl transferase in human cancer.

Y. Bignon, F. Penault-Llorca, M. Ngollo, 2015, Epigenomics.

Gene‐ and pathway‐level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility

E. Barillot, P. Guénel, T. Truong, 2020, International journal of cancer.

TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer

Y. Bignon, M. Mouret-Reynier, C. Abrial, 2017, Oncotarget.

Mutation analysis of PALB2 gene in French breast cancer families

D. Stoppa-Lyonnet, O. Sinilnikova, S. Mazoyer, 2015, Breast Cancer Research and Treatment.

Mutation Screening of the BRCA1 Gene in Early Onset and Familial Breast/Ovarian Cancer in Moroccan Population

Y. Bignon, S. Amzazi, N. Uhrhammer, 2012, International journal of medical sciences.

miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers

Y. Bignon, F. Penault-Llorca, M. Trimèche, 2017, Pathology & Oncology Research.

RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

F. Couch, O. Olopade, T. Rebbeck, 2007, American journal of human genetics.

The association between Histone 3 Lysine 27 Trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters

Y. Bignon, A. Lebert, F. Penault-Llorca, 2014, BMC Cancer.

Prostate cancer: The main risk and protective factors-Epigenetic modifications.

Y. Bignon, F. Penault-Llorca, S. Karsli-Ceppioglu, 2015, Annales d'endocrinologie.

Gene panel model predictive of outcome in patients with prostate cancer.

Y. Bignon, B. Terris, A. Vieillefond, 2013, Omics : a journal of integrative biology.

Feedback of extended panel sequencing in 1530 patients referred for suspicion of hereditary predisposition to adult cancers

Y. Bignon, N. Uhrhammer, Y. Bidet, 2020, Clinical genetics.

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

Laetitia Huiart, Dominique Leroux, Bernard Bonaïti, 2011, JAMA.

High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.

Y. Bignon, F. Penault-Llorca, G. Judes, 2016, Cancer letters.

Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines.

Y. Bignon, M. Ngollo, Julie Durif, 2013, Epigenomics.

Can soy phytoestrogens decrease DNA methylation in BRCA1 and BRCA2 oncosuppressor genes in breast cancer?

Y. Bignon, P. Dechelotte, Rémy Bosviel, 2012, Omics : a journal of integrative biology.

Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation

D. Stoppa-Lyonnet, S. Mazoyer, F. Damiola, 2021, Breast cancer research : BCR.

Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population

S. Ahmed, Y. Bignon, L. Chouchane, 2011, Molecular Biology Reports.

Use of Gene Expression Profiles of Peripheral Blood Lymphocytes to Distinguish BRCA1 Mutation Carriers in High Risk Breast Cancer Families

V. Chabaud, Y. Bignon, F. Kwiatkowski, 2009, Cancer informatics.

Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?

Y. Bignon, L. Chouchane, N. Uhrhammer, 2007, European journal of histochemistry : EJH.

Expression profiling by whole-genome microarray hybridization reveals differential gene expression in breast cancer cell lines after lycopene exposure.

Y. Bignon, N. Chalabi, L. Delort, 2007, Biochimica et biophysica acta.

Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families

A. Aurias, D. Stoppa-Lyonnet, P. Pujol, 2002, Oncogene.

Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.

C. Bonaïti‐pellié, L. Essioux, O. Sinilnikova, 1998, American journal of medical genetics.

Attitudes towards cancer predictive testing and transmission of information to the family.

Y. Bignon, H. Sobol, C. Julian‐Reynier, 1996, Journal of medical genetics.

Epigenetic modifications in prostate cancer.

Y. Bignon, F. Penault-Llorca, S. Karsli-Ceppioglu, 2014, Epigenomics.

Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases’ occurrence

S. Mader, Y. Bignon, H. Khodjet-el-khil, 2014, Medical Oncology.

Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer.

Y. Bignon, L. Chouchane, A. Elgaaied, 2008, Cancer Biomarkers.

Loss of heterozygosity at the ATM locus in colorectal carcinoma.

Y. Bignon, F. Kwiatkowski, J. Bay, 1999, Oncology reports.

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

R. Eeles, J. Hopper, D. Easton, 2021, American journal of obstetrics and gynecology.

Expression of a retinoblastoma transgene results in dwarf mice.

Y. Chen, D. Riley, W. Lee, 1993, Genes & development.

Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing

X. Yi, Y. Bignon, Yuhua Gong, 2014, Familial Cancer.

Dual genotype in cutaneous T cell lymphoma: immunoglobulin gene rearrangement in clonal T cell malignancy.

Y. Bignon, P. Souteyrand, D. Bernard, 1989, The Journal of investigative dermatology.

Positive link between variant Toll-like receptor 4 (Asp299Gly and Thr399Ile) and colorectal cancer patients with advanced stage and lymph node metastasis

Y. Bignon, N. Kourda, N. Uhrhammer, 2013, Tumor Biology.

Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).

Y. Bignon, Y J Bignon, B Aunoble, 2000, International journal of oncology.

Anti‐EGFR monoclonal antibodies enhance sensitivity to DNA‐damaging agents in BRCA1‐mutated and PTEN‐wild‐type triple‐negative breast cancer cells

Y. Bignon, F. Penault-Llorca, C. Aubel, 2017, Molecular carcinogenesis.

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

Y. Bignon, F. Kwiatkowski, F. Penault-Llorca, 2016, Oncotarget.

Biological basis of cancer predisposition

Y. Bignon, 2004 .

Dual genotype in cutaneous T-cell lymphomas and pseudolymphomas

B. Dastugue, Y. Bignon, P. Souteyrand, 2004, Human Genetics.

[Mutation by deletion-insertion in BRCA-1 gene in three unrelated French breast/ovarian cancer families: possible implication of a mobile element].

Y. Bignon, A. Hardouin, N. Presneau, 1999, Bulletin du cancer.

H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes.

Y. Bignon, A. Lebert, F. Penault-Llorca, 2016, Epigenomics.

Epigenetic mechanisms of breast cancer: an update of the current knowledge.

Y. Bignon, F. Penault-Llorca, S. Karsli-Ceppioglu, 2014, Epigenomics.

Epigenetic modulation of BRCA 1 and BRCA 2 gene expression by equol in breast cancer cell lines

Y. Bignon, P. Dechelotte, Rémy Bosviel, 2012 .

Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene

Y. Bignon, J. Maurizis, P. Rio, 1999, International journal of cancer.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group.

M. Beckmann, T. Sellers, M. Stratton, 2000, American journal of human genetics.

TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing

J. Lemonnier, N. Sevenet, D. Stoppa-Lyonnet, 2021, Cancers.

The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

W. Chung, F. Couch, O. Olopade, 2021, Genetics in Medicine.

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

F. Couch, B. Karlan, J. Benítez, 2011, Journal of the National Cancer Institute.

DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.

Fabrice Kwiatkowski, Frédérique Penault-Llorca, F. Penault-Llorca, 2015, American journal of cancer research.

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers

D. Stoppa-Lyonnet, S. Mazoyer, C. Houdayer, 2018, Front. Oncol..

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS Genetics.

GENESIS: a French national resource to study the missing heritability of breast cancer

D. Stoppa-Lyonnet, O. Sinilnikova, S. Mazoyer, 2016, BMC Cancer.

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, Breast Cancer Research.

Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, PloS one.

phylogenetic approach identified mitochondrial haplogroup T 1 a 1 as inversely associated with breast cancer risk in BRCA 2 mutation carriers

W. Chung, D. Steinemann, V. Pankratz, 2015 .

Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

F. Couch, T. Rebbeck, J. Benítez, 2010, Cancer Epidemiology, Biomarkers & Prevention.

BRCA Share: A Collection of Clinical BRCA Gene Variants

Christophe Béroud, Dominique Vaur, Izabela Karbassi, 2016, Human mutation.

Giant cell tumor of the sternum. Report of a case with a 17q isochromosome.

Y. Bignon, J. Bay, D. Hauteville, 1999, Revue du rhumatisme.

No evidence for constitutional ATM mutation in breast/gastric cancer families.

R. Gatti, Y. Bignon, J. Bay, 1998, International journal of oncology.

Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among families with BRCA1/2 or MMR gene mutations

M. Picot, J. Solassol, P. Pujol, 2019, Psycho-oncology.

Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer

Marc Vidal, Dieter Niederacher, Roderic Guigó, 2011, PLoS biology.

Downregulation of BRCA1 in A375 melanoma cell line increases radio-sensitivity and modifies metastatic and angiogenic gene expression.

J. Madelmont, Y. Bignon, C. Hesling, 2004, The Journal of investigative dermatology.

p16 involvement in primary bladder tumors: analysis of deletions and mutations.

Y. Bignon, P. Catilina, E. Baud, 1999, International journal of oncology.

SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer

Y. Bignon, F. Penault-Llorca, G. Judes, 2018, Oncotarget.

Effectiveness of a Global Multidisciplinary Supportive and Educational Intervention in Thermal Resort on Anthropometric and Biological Parameters, and the Disease-Free Survival after Breast Cancer Treatment Completion (PACThe)

Y. Bignon, A. Rossary, M. Vasson, 2020, Journal of oncology.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

B. Nilsson, R. Klein, B. Pégourié, 2019, Leukemia.

Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients

A. Børresen-Dale, J. Bergh, A. Langerød, 2005, Breast Cancer Research.

AKT and p 21 WAF 1 / CIP 1 as Potential Genistein Targets in BRCA 1-mutant Human Breast Cancer Cell Lines

Y. Bignon, M. Ferrara, C. Aubel, 2010 .

Significant association between interleukin-17A polymorphism and colorectal cancer

Y. Bignon, N. Kourda, N. Uhrhammer, 2014, Tumor Biology.

Improved Efficiency and Reliability of NGS Amplicon Sequencing Data Analysis for Genetic Diagnostic Procedures Using AGSA Software

Axel Poulet, Y. Bignon, N. E. El Saghir, 2016, BioMed research international.

Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study.

Katherine M. Tucker, Aung Ko Win, Swati G. Patel, 2021, The Lancet. Oncology.

BRCA 1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells

N. Radosevic-Robin, D. Morvan, Y. Bignon, 2017 .

BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells

F. Penault-Llorca, N. Radosevic-Robin, D. Morvan, 2014, PloS one.

Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers

Y. Bignon, F. Penault-Llorca, F. Ponelle, 2015, Cellular Oncology.

[Cutaneous pseudolymphoma caused by carbamazepine].

Y. Bignon, P. Souteyrand, P. Dechelotte, 1998, Annales de dermatologie et de venereologie.

Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

Y. Bignon, M. Ferrara, S. Lafarge, 2001, Oncogene.

Rare duplication of the CDC73 gene and atypical hyperparathyroidism‐jaw tumor syndrome: A case report and review of the literature

Y. Bignon, N. Uhrhammer, M. Batisse-Lignier, 2023, Molecular genetics & genomic medicine.

The 1396del a mutation and a missense mutation or a rare polymorphism of the WRN gene detected in a French Werner family with a severe phenotype and a case of an unusual vulvar cancer

Y. Bignon, J. Bay, M. Ferrara, 1998, Human mutation.

Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene

V. Gaborieau, D. Yannoukakos, J. Peyrat, 2005, International journal of cancer.

The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer

Y. Bignon, A. Lebert, F. Penault-Llorca, 2017, Scientific Reports.

Breast cancer: mechanisms involved in action of phytoestrogens and epigenetic changes.

Y. Bignon, M. Ngollo, Julie Durif, 2013, In vivo.

BRCA2 promoter hypermethylation in sporadic breast cancer.

Y. Bignon, F. Kwiatkowski, Rémy Bosviel, 2012, Omics : a journal of integrative biology.

A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2

Y. Bignon, F. Penault-Llorca, L. Guy, 2018, Oncotarget.

EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer.

Y. Bignon, F. Penault-Llorca, L. Guy, 2017, Omics : a journal of integrative biology.

Histone Methylation in Relation with Clinical Pathological Parameters in Prostate Cancer

Y. Bignon, F. Penault-Llorca, L. Guy, 2017 .

Differential expressions of BRCA1 and BRCA2 in infantile gynecomastia.

Y. Bignon, L. Le Corre, N. Chalabi, 2004, Anticancer research.

Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.

M. D. De Latour, Y. Bignon, L. Le Corre, 2003, Anticancer research.

Involvement of IL17A, IL17F and IL23R Polymorphisms in Colorectal Cancer Therapy

Y. Bignon, N. Kourda, N. Uhrhammer, 2015, PloS one.

Unclassified sequence variants (UVS) and genetic predisposition to cancer

E. Carasevici, Y. Bignon, N. Uhrhammer, 2010 .

AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.

Y. Bignon, M. Ferrara, C. Aubel, 2010, Anticancer research.

Comparative Effects of Soy Phytoestrogens and 17β-Estradiol on DNA Methylation of a Panel of 24 Genes in Prostate Cancer Cell Lines

Y. Bignon, A. Lebert, F. Penault-Llorca, 2014, Nutrition and cancer.

Long-term improvement of breast cancer survivors’ quality of life by a 2-week group physical and educational intervention: 5-year update of the ‘PACThe’ trial

Y. Bignon, M. Vasson, M. Duclos, 2017, British Journal of Cancer.

European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables

M. Beckmann, A. Børresen-Dale, D. Birnbaum, 1999, British Journal of Cancer.

A single Cys706 to Phe substitution in the retinoblastoma protein causes the loss of binding to SV40 T antigen.

D. Rappolee, S. Naylor, W. Lee, 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

AKT and p21WAF1/CIP1 as Potential Genistein Targets in BRCA1-mutant Human Breast Cancer Cell Lines

Y. Bignon, M. Ferrara, C. Aubel, 2010 .

Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium

S. Seal, M. Stratton, N. Rahman, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer.

Y. Bignon, A. Benammar Elgaaied, N. Kourda, 2014, Immunology letters.

Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer

Y. Bignon, F. Penault-Llorca, G. Judes, 2017, Oncotarget.

Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer

F. Penault-Llorca, Y. Bignon, F. Kwiatkowski, 2017, PloS one.

Human Cancer Biology MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

M. Urioste, P. Chanson, M. Blok, 2012 .

Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression

Y. Bignon, A. Lebert, F. Penault-Llorca, 2017, BMC Cancer.

Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.

Y. Bignon, A. Lebert, F. Penault-Llorca, 2016, Cancer genomics & proteomics.

Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability.

F. Penault-Llorca, Y. Bignon, F. Kwiatkowski, 1998, International journal of oncology.

The Role of Soy Phytoestrogens on Genetic and Epigenetic Mechanisms of Prostate Cancer.

Y. Bignon, F. Penault-Llorca, S. Karsli-Ceppioglu, 2015, The Enzymes.

Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition

I. Bièche, V. Chabaud, J. Peyrat, 2012, Breast Cancer Research and Treatment.

Genotyping of cutaneous T-cell lymphomas and pseudolymphomas.

Y. Bignon, P. Souteyrand, 1989, Current problems in dermatology.

MicroRNAs 146a and 147b Biomarkers for Colorectal Tumor's Localization

Y. Bignon, N. Kourda, N. Uhrhammer, 2014, BioMed research international.

Cancer genetics clinics: target population and consultees' expectations.

Y. Bignon, H. Sobol, C. Julian‐Reynier, 1996, European journal of cancer.

Association between genetic polymorphisms and ovarian cancer risk.

Y. Bignon, F. Kwiatkowski, N. Chalabi, 2008, Anticancer research.

Gene expression profiling of breast cancer cell lines in response to soy isoflavones using a pangenomic microarray approach.

Y. Bignon, N. Chalabi, Samir Satih, 2010, Omics : a journal of integrative biology.

Isolation, purification and quantification of BRCA1 protein from tumour cells by affinity perfusion chromatography.

Y. Bignon, J. Chassagne, C. Hızel, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Immunolocalization of BRCA 1 protein in tumor breast tissue : prescreening of BRCA 1 mutation in Tunisian patients with hereditary breast cancer ?

Y. Bignon, L. Chouchane, A. Elgaaied, 2007 .

ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis

Y. Bignon, C. Abrial, F. Kwiatkowski, 2016, The journal of pathology. Clinical research.

Neoadjuvant chemotherapy in 126 operable breast cancers.

Y. Bignon, F. Kwiatkowski, P. Chollet, 1992, European journal of cancer.

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

Katherine M. Tucker, L. Kiemeney, H. Grönberg, 2011, BJU international.

Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer

Y. Bignon, F. Penault-Llorca, M. Idrissou, 2018, Cancers.

Phytoestrogens regulate the expression of genes involved in different biological processes in BRCA2 knocked down MCF-7, MDA-MB-231 and MCF-10a cell lines.

Y. Bignon, N. Chalabi, Samir Satih, 2010, Oncology reports.

International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation

M. King, W. Foulkes, C. Lázaro, 2011, Breast Cancer Research and Treatment.

Gene signature of breast cancer cell lines treated with lycopene.

Y. Bignon, L. Le Corre, N. Chalabi, 2006, Pharmacogenomics.

Transcriptional Profiling of Breast Cancer Cells Exposed to Soy Phytoestrogens After BRCA1 Knockdown With a Whole Human Genome Microarray Approach

Y. Bignon, N. Chalabi, Samir Satih, 2010, Nutrition and cancer.

Identification of a novel pathogenic variant in PALB2 and BARD1 genes by a multigene sequencing panel in triple negative breast cancer in Morocco

B. Badaoui, Y. Bignon, N. Uhrhammer, 2021, Journal of genomics.

Cancer genetic clinics: why do women who already have cancer attend?

Y. Bignon, H. Sobol, C. Julian‐Reynier, 1998, European journal of cancer.

Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population

S. Ahmed, Y. Bignon, L. Chouchane, 2011, Molecular Biology Reports.

Rad50 c.687delT Does Not Contribute Significantly to Familial Breast Cancer in a French Population

Y. Bignon, N. Uhrhammer, L. Delort, 2009, Cancer Epidemiology Biomarkers & Prevention.

BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer

Y. Bignon, M. Duclos, F. Kwiatkowski, 2019, Hereditary Cancer in Clinical Practice.

Les tests génétiques en cancérologie pédiatrique genetic testing in pediatric oncology

Y. Bignon, 2003 .

Positive and cost-effectiveness effect of spa therapy on the resumption of occupational and non-occupational activities in women in breast cancer remission: a French multicentre randomised controlled trial.

Y. Bignon, F. Kwiatkowski, L. Gerbaud, 2014, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Differential Expression of Genes Induced by Resveratrol in Human Breast Cancer Cell Lines

Y. Bignon, L. Le Corre, N. Chalabi, 2006, Nutrition and cancer.

Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast Cancer.

M. Campone, F. Magrangeas, S. Minvielle, 2006, Cancer genomics & proteomics.

Brca1 and Brca2 protein expression patterns in different tissues of murine origin.

M. D. De Latour, Y. Bignon, J. Chassagne, 2001, International journal of oncology.

TIP60 Histone Acetyltransferase in Adipose Tissue: Possible Linkages with Breast Cancer Development?

Y. Bignon, F. Penault-Llorca, G. Judes, 2017, Omics.

Digging Deeper into Breast Cancer Epigenetics: Insights from Chemical Inhibition of Histone Acetyltransferase TIP60 In Vitro.

Y. Bignon, A. Lebert, F. Penault-Llorca, 2020, Omics : a journal of integrative biology.

Nijmegen breakage syndrome gene (NBS1) is not the tumor suppressor gene at 8q21.3 involved in colorectal carcinoma.

K. Sperling, Y. Bignon, N. Uhrhammer, 2002, Oncology reports.

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells

Y. Bignon, F. Penault-Llorca, C. Aubel, 2020, Scientific Reports.

BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer

Y. Bignon, M. Duclos, F. Kwiatkowski, 2019, Hereditary cancer in clinical practice.

miRNAs differentially expressed in prostate cancer cell lines after soy treatment.

Y. Bignon, Rémy Bosviel, Luc Fontana, 2011, In vivo.

Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue.

Y. Bignon, A. Lebert, F. Penault-Llorca, 2014, Omics.

Treatment With Lycopene and Correlation With RT-QPCR , and Cx43 in Breast Tumor Cell Lines After β , RAR α Immunohistochemical Expression of RAR

Y. Bignon, L. Delort, N. Chalabi, 2013 .

Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.

Y. Bignon, D. Bernard-Gallon, B. Aunoble, 2001, Oncology reports.

Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I

S. Richard, R. Lidereau, D. Stoppa-Lyonnet, 2021, Human mutation.

Expression of human BRCA1 and BRCA2 proteins in lung from a fetus at 19 weeks' gestation

Y. Bignon, P. Dechelotte, P. Rio, 1999, International journal of cancer.

Seventh International Workshop on Ataxia-Telangiectasia.

Y. Bignon, J. Bay, N. Uhrhammer, 1998, Cancer research.

Allelic imbalance at NBS1 is frequent in both proximal and distal colorectal carcinoma.

Y. Bignon, F. Kwiatkowski, J. Bay, 2000, Oncology reports.

BRCA2 protein expression in sporadic breast carcinoma with or without allelic loss of BRCA2

Y. Bignon, C. Hızel, P. Rio, 2000, International journal of cancer.

3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer

Y. Bignon, N. Uhrhammer, R. Marrakchi, 2014, Medical Oncology.

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

J Chang-Claude, M. Stratton, J. Chang-Claude, 1998, American journal of human genetics.

[The retinoblastoma gene: will therapeutic use of its tumor suppressive properties be possible?].

Y. Bignon, P. Rio, 1993, Bulletin du cancer.

Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing

X. Yi, Y. Bignon, Yuhua Gong, 2015, Familial Cancer.

Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing.

J. Vermeesch, L. Dehaspe, G. Matthijs, 2012, The Journal of molecular diagnostics : JMD.

TIP60 Inhibitor TH1834 Reduces Breast Cancer Progression in Xenografts in Mice.

Y. Bignon, S. Besse, F. Penault-Llorca, 2019, Omics.

Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers

Y. Bignon, F. Penault-Llorca, F. Ponelle, 2015, Cellular Oncology.

TIP60/P400/H4K12ac Plays a Role as a Heterochromatin Back-up Skeleton in Breast Cancer

Y. Bignon, F. Penault-Llorca, Anna Sanchez, 2020, Cancer Genomics & Proteomics.

BRCA1 is localized in ductal secretions of normal breast tissues: Detection by antibodies raised against the amino terminus of BRCA1 (K‐18)

Y. Bignon, C. Hızel, P. Rio, 1998, International journal of cancer.

BRCA1 and BRCA2 proteins are expressed in milk fat globules

Y. Bignon, P. Dechelotte, P. Rio, 1999, International journal of cancer.

Cross‐reaction between antibodies raised against the last 20 C‐terminal amino acids of BRCA 1 (C‐20) and human EGF and EGF‐R in MCF 10a human mammary epithelial cell line

Y. Bignon, J. Maurizis, D. Bernard-Gallon, 1997, International journal of cancer.

Whole genome approach to basal like breast cancer

F. Penault-Llorca, Y. Bignon, N. Uhrhammer, 2011 .

Role of JMJD3 Demethylase and Its Inhibitor GSK-J4 in Regulation of MGMT, TRA2A, RPS6KA2, and U2AF1 Genes in Prostate Cancer Cell Lines.

Y. Bignon, F. Penault-Llorca, L. Guy, 2020, Omics : a journal of integrative biology.

Is BRCA2 involved in early onset colorectal cancer risk?

Y. Bignon, N. Barnich, N. Uhrhammer, 2019, Clinical genetics.

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

J. Lemonnier, P. Pujol, J. Fricker, 2012, Familial Cancer.

BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite

Y. Bignon, L. Cravello, P. Dechelotte, 2000, Breast Cancer Research.

Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort.

Y. Bignon, A. Chamoux, L. Delort, 2009, Anticancer research.

[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].

Y. Bignon, B. Morio, X. Durando, 2013, Bulletin du cancer.

[Physical activity and cancer survival].

B. Fervers, I. Romieu, G. Romieu, 2012, Bulletin du Cancer.